New data published in Journal of Clinical Sleep Medicine shows Philips Trilogy and Patient Management Program helps reduce COPD readmissions by 97 percent

Latest study of non-invasive ventilators underscores importance for connected care and optimized management of COPD patients

July 15, 2015

Andover, Mass. – With more than 15 million adults in the U.S. living with chronic obstructive pulmonary disease (COPD) and hospitals under increasing pressure to adhere to 30-day COPD readmissions standards, new research published in the Journal of Clinical Sleep Medicine highlights non-invasive ventilation as a key part of a multi-faceted intervention approach to successfully reduce readmission rates among COPD patients. The study, funded and co-authored by Royal Philips (NYSE: PHG, AEX: PHIA), evaluated COPD patients who were hospitalized two or more times within a year and transitioned to a COPD patient management program, which included treating those same patients with noninvasive positive pressure ventilation (NIPPV). The results of the study showed that the readmission rate was reduced by 97 percent during the subsequent 12 months. The study used Philips Respironics Trilogy 100 to deliver the NIPPV therapy to the study patients.


In the U.S., costs for hospital stays for patients with COPD as a principal diagnosis has been projected to be approximately $29.5 billion.[1] The readmission rate within 30 days of discharge for patients with COPD has been reported to be as high as 22.6%.[2] In this study, the proportion of COPD patients who were readmitted on two or more occasions decreased from 100% (397 of 397) in the year prior to initiation of intervention to 2.2% (9 of 397) in the following year.


“The results of this study indicate that Philips Trilogy with an advanced mode of ventilation AVAPs-AE therapy – in combination with respiratory therapist-led care, medication reconciliation and adequate provision of oxygen therapy – assisted in stabilizing the respiratory condition of patients with COPD,” said Amy Day, RRT, Director of Ventilation Management of Barnes Healthcare Services. “Such better management of the COPD condition allows health systems to not only significantly reduce readmissions and the associated high costs, but also improve the quality of life for some of its most complex patients.”


The study, entitled “Retrospective Assessment of Home Ventilation to Reduce Rehospitalization in Chronic Obstructive Pulmonary Disease” and authored by Steven Coughlin, PhD, Wei Liang, PhD and Sairam Parthasarathy, MD, examined 397 patients who had all been hospitalized at least twice in a single year with an acute COPD exacerbation. Each patient was prescribed a Trilogy ventilator manufactured by Philips Respironics for home use.  Continued in home care consisted of medication management, oxygen therapy, patient education and ongoing respiratory therapist care in the home.


“This study holds promise in how a multi-faceted intervention could assist health systems in significantly improving the care of the patients with advanced stage COPD in their home,” said Sairam Parthasarathy, MD, Professor of Medicine and Director of the Center for Sleep Disorders at Banner – University Medical Center Tucson. “The results indicate that patients placed on this advanced mode of non-invasive ventilation, combined with an in-home care program, can reduce hospitalizations and subsequently reduce healthcare utilization. This study is a good foundation to build from and to further validate.”


Connected COPD Care

With more treatments available to them today than ever before, COPD patients are living longer after diagnosis. Home, portable non-invasive ventilators help homecare providers manage more patients with fewer resources, while allowing patients to live healthy lives at home.

“The results of this are more critical now more than ever, given the industry’s increased focus on the high cost of chronic diseases and the need to reduce the re-hospitalization of COPD patients,” said Eli Diacopoulos, Vice President and General Manager, Philips Respironics. “The use of Trilogy in this COPD management program is just one example of our ability to work with an innovative homecare provider partner to achieve a new kind of COPD care management model that connects and supports the clinician, caregiver, home care provider and the patient at every point along the patient care path.”


Philips Respironics is committed to innovating patient-centered COPD care management models. Philips is currently piloting a COPD care model that utilizes Bluetooth-enabled Trilogy devices and a tablet application tool to optimize clinician, caregiver and homecare provider coordination. This pilot is Philips Respironics’ next step toward connected homecare solutions for respiratory patients.


For more information on Philips’ portfolio of connected sleep and respiratory care solutions, follow @PhilipsResp and the Philips Respironics Facebook page.


[1] Confronting COPD in America, 2000. Schulman, Ronca and Bucuvalas, Inc. (SRBI) Funded by Glaxo Smith Kline

[2] Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. April 2 2009;360(14):1478-1428.

For further information, please contact:

Alicia Cafardi





About Royal Philips:

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at


You are about to visit a Philips global content page

You are about to visit the Philips USA website.

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.